Table 4. Prediction of survival and recurrence in the HBV-HCC population.
| Factors | OS | RFS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR(95%CI) | P | HR(95%CI) | P | HR(95%CI) | P | HR(95%CI) | P | |
| Testing Set (n=108) | ||||||||
| ALB (g/L) (≤41 v >41) | 0.557(0.358-0.864) | 0.003 | 0.061 | 0.612(0.402-0.933) | 0.007 | 0.123 | ||
| Tumor number (single v multiple) | 1.795(1.093-2.946) | 0.008 | 2.164(1.295-3.618) | 0.003 | 1.467(0.900-2.391) | 0.072 | NA | |
| Vascular invasion (yes v no) | 0.440(0.285-0.680) | <0.001 | 0.580(0.370-0.909) | 0.018 | 0.459(0.300-0.702) | 0.014 | 0.596(0.381-0.933) | 0.024 |
| Tumor encapsulation (yes v no) | 1.723(0.970-3.059) | 0.032 | 0.461 | 1.476(0.879-2.477) | 0.081 | NA | ||
| Tumor size (≤5.0 v >5.0) | 2.739(1.737-4.319) | <0.001 | 2.665(1.668-4.258) | <0.001 | 2.729(1.750-4.257) | <0.001 | 2.462(1.552-3.905) | <0.001 |
| TNM stage (I-II v III A) | 2.160(1.398-3.336) | <0.001 | 0.952 | 2.024(1.331-3.076) | 0.001 | 0.618 | ||
| Metavir score (F1-3/4) | 1.590(1.019-2.481) | 0.020 | 0.467 | 1.678(1.090-2.583) | 0.006 | 0.920 | ||
| FIB-4 (I/II) | 1.751(1.125-2.727) | 0.005 | 1.766(1.117-2.793) | 0.015 | 2.061(1.330-3.195) | <0.001 | 2.057(1.308-3.236) | 0.002 |
| Combined M+F | 2.984(1.672-3.784) | <0.001 | 3.027 (1.223-4.387) | <0.001 | 2.997(1.235-3.882) | <0.001 | 2.783(1.098-3.776) | <0.001 |
| Validation Set (n=324) | ||||||||
| ALB (g/L) (≤44 v >44) | 0.657(0.434-0.994) | 0.045 | 0.474 | 0.838(0.608-1.156) | 0.279 | NA | ||
| TB (mg/dl) (≤0.93 v >0.93) | 0.642(0.416-0.989) | 0.043 | 0.619(0.398-0.962) | 0.033 | 0.744(0.532-1.040) | 0.082 | NA | |
| AST(U/L) (≤47 v >47) | 1.759(1.174-2.635) | 0.006 | 0.209 | 1.525(1.096-2.121) | 0.010 | 0.343 | ||
| AFP (ng/ml) (≤20 v >20) | 1.530(1.001-2.337) | 0.048 | 0.341 | 1.589(1.135-2.224) | 0.005 | 0.174 | ||
| Tumor number (single v multiple) | 2.224(1.373-3.602) | 0.001 | 2.563(1.568-4.188) | <0.001 | 1.728(1.140-2.620) | 0.008 | 1.740(1.143-2.647) | 0.010 |
| Vascular invasion (yes v no) | 2.016(1.342-3.027) | 0.001 | 1.710(1.130-2.587) | 0.011 | 2.164(1.561-3.000) | <0.001 | 1.933(1.380-2.708) | <0.001 |
| Tumor size (≤5.0 v >5.0) | 2.848(1.921-4.221) | <0.001 | 2.984(1.991-4.473) | <0.001 | 2.364(1.721-3.248) | <0.001 | 2.200(1.589-3.046) | <0.001 |
| TNM stage (I-II v III A) | 1.750(1.070-2.862) | 0.024 | 0.108 | 1.758(1.178-2.623) | 0.004 | 1.671(1.105-2.528) | 0.015 | |
| Metavir score (F1-3/4) | 1.602(1.082-2.373) | 0.018 | 1.702(1.130-2.613) | 0.015 | 1.377(1.005-1.886) | 0.045 | 0.051 | |
| FIB-4 (I/II) | 1.648(1.100-2.468) | 0.014 | 1.662(1.071-2.579) | 0.023 | 1.593(1.149-2.209) | 0.005 | 1.663(1.197-2.312) | 0.002 |
| Combined M+F | 3.232(1.893-5.434) | <0.001 | 3.332 (1.726-5.987) | <0.001 | 2.985(1.223-3.497) | <0.001 | 2.537(1.035-3.765) | <0.001 |
Univariate analysis: Kaplan-Meier method; multivariate analysis: Cox proportional hazards regression model. Abbreviations: OS: overall survival; TTR: time to recurrence; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; ALB: Albumin; Combination M+F: combination of Metavir+FIB-4 scores; NA: not adopted.